Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CERS vs COCH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CERS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)
CERS Overall Winner
6-Pillar Tally: CERS 5 – 1 COCH
Matrix Metrics: CERS 5 – 4 COCH
As of Nov 20, 2026, Cerus Corp (CERS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CERS carries a Unified Composite Score of 55.5/100 (HOLD) at $1.85 (123.3x Forward P/E, -1.1% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin).
- Growth vs. Quality Trade-Off: CERS earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. COCH 35.1/100 SELL) and 1.51β · 76% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: CERS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0); meanwhile COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CERS vs COCH
CERS
Head-to-Head Winner
Cerus Corp
$1.85
-2.63% 1D
Market Cap
$383.7M
TTM Revenue
$227M
Forward P/E
123.3x
Beta / 30D Vol
1.51β · 76% Vol
Unified Composite Score
55.5
HOLD
Tech 60.0
Fund 64.0
Flow 66.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
COCH
Envoy Medical, Inc. Class A Common Stock
$6.70
+0.0% 1D
Market Cap
$51.9M
TTM Revenue
$231,000
Forward P/E
N/M
Beta / 30D Vol
4.94β · 3352% Vol
Unified Composite Score
35.1
SELL
Tech 50.0
Fund 27.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (CERS 5 – 1 COCH)
1. Valuation Multiples
CERS
Forward P/E
123.3x
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
2.0x
119.2x
2. Growth & Scale
CERS
Revenue Growth (YoY)
+9.5%
+57.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$227M
$231,000
Market Cap
$383.7M
$51.9M
3. Profitability & Quality
CERS
Gross Margin
51.8%
N/A
Operating Margin
-1.1%
-10261.0%
Net Profit Margin
-3.2%
0.0%
Return on Equity (ROE)
-10.7%
0.0%
4. Balance Sheet & Cash Flow
CERS
Cash Generation (TTM)
$494,000
-$21M
Cash Flow Margin
0.2%
N/A
Net Cash / Leverage
$59M Net Debt (0.99x D/E)
$24M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
COCH
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
59.8% (32nd %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
CERS
OpEx & R&D Intensity
52.9% of Rev ($120M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CERS (5) vs COCH (4)| Institutional Metric | CERS | COCH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $383.7M | $51.9M | CERS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | 123.3x | N/M | CERS | |
| Revenue Growth (YoY) | +9.5% | +57.1% | COCH | |
| Operating Margin (TTM) | -1.1% | -10261.0% | CERS | |
| Net Profit Margin | -3.2% | 0.0% | COCH | |
| Return on Equity (ROE) | -10.7% | 0.0% | COCH | |
| 52-Week Range Position | 19% ($1–$3) | 89% ($0–$7) | COCH | |
| Beta / 30D Volatility | 1.51β · 76% Vol | 4.94β · 3352% Vol | CERS | |
| Unified Institutional Score | 55.5 / 100 (HOLD) | 35.1 / 100 (SELL) | CERS | |
| Trailing 12M Revenue (USD) | $227M | $231,000 | Scale | |
| Gross Profit Margin (TTM) | 51.8% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 2.0x EV/Rev | N/M PEG · 119.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $494,000 ($59M Net Debt (0.99x D/E)) | -$21M ($24M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
COCH +1044.26 pp
3M Horizon
COCH +829.11 pp
6M Horizon
COCH +876.72 pp
1Y Horizon
COCH +820.88 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CERS Revenue | COCH Revenue | CERS Op. Margin | COCH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $80M | N/A | -72.3% | N/A | CERS |
| FY2019 | $90M | N/A | -70.6% | N/A | CERS |
| FY2020 | $110M | N/A | -51.1% | N/A | CERS |
| FY2021 | $160M | N/A | -30.7% | N/A | CERS |
| FY2022 | $190M | $0M | -18.1% | -3673.4% | CERS |
| FY2023 | $190M | $0M | -16.1% | -5809.8% | CERS |
| FY2024 | $200M | $0M | -7.1% | -8558.2% | CERS |
| FY2025 | $230M | $0M | -3.7% | -9240.7% | CERS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CERS
BREAKDOWN
Current IV
59.8%
IV Percentile
32nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CERS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
COCH
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CERS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
52.9% of Rev ($120M)
90D Engineering Disclosures
0 Published
COCH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CERS vs COCH Key Questions & Quantitative Answers
As of Nov 20, 2026, Cerus Corp (CERS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CERS carries a Unified Composite Score of 55.5/100 (HOLD) at $1.85 (123.3x Forward P/E, -1.1% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin). Growth vs. Quality Trade-Off: CERS earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. COCH 35.1/100 SELL) and 1.51β · 76% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CERS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0); meanwhile COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CERS leads the Growth & Scale pillar: CERS posts +9.5% YoY revenue growth and +0.0% YoY earnings growth on $227M TTM revenue (51.8% gross margin, -1.1% operating margin), compared with COCH at +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CERS cumulative revenue shifted +187.5% while COCH shifted N/A. In operating R&D and SG&A reinvestment, CERS deploys 52.9% of Rev ($120M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCH.
CERS screens cheaper on headline valuation multiples. CERS trades at 123.3x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.0x EV/Revenue (0.2% FCF margin), whereas COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CERS (-10.7% ROE) versus COCH (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CERS carries 59.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.51β · 76% Vol realized risk). By comparison, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
COCH vs CERS · Reverse Pair
CERS vs VCYT
· Sector Peer
CERS vs BCRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal